Literature DB >> 18695537

Surgery of extra-axial tumors of the cerebral base.

Madjid Samii1, Venelin M Gerganov.   

Abstract

Because of the complex structure of the cranial base and its close proximity to cranial nerves and vessels, surgery in this area is associated with considerable risk of morbidity and mortality. Multiple approaches to each part of the cranial base have been developed over the past few decades, ranging from small modifications of more traditional approaches to complex and sophisticated new techniques. However, experience has shown that optimal outcome is achieved if the selected approach is not associated with significant approach-related morbidity. Furthermore, not all cranial base tumors can be cured by surgery. The selection of operative approach and the goal of surgery should be part of the whole treatment strategy. The attempt to achieve complete resection can, therefore, be justified only if the associated long-term morbidity is minimal. Refinements of the traditional retrosigmoid suboccipital approach have made it the most effective and safe approach, the "gold standard" for lesions in the cerebellopontine angle. On the other hand, in some basal tumors, e.g., chordomas and chondrosarcomas, the approach has to be selected individually and must always be tailored to the characteristics of the particular tumor, its location, and the patient's expectations. The expertise of the surgeon is not reflected in his or her ability to perform the most complex approaches but in the ability to select the approach that affords both removal of the tumor and preservation of patient's neurological function and quality of life.

Entities:  

Mesh:

Year:  2008        PMID: 18695537     DOI: 10.1227/01.neu.0000333782.19682.76

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  8 in total

1.  5-Aminolevulinic acid-induced protoporphyrin IX fluorescence in meningioma: qualitative and quantitative measurements in vivo.

Authors:  Pablo A Valdes; Kimon Bekelis; Brent T Harris; Brian C Wilson; Frederic Leblond; Anthony Kim; Nathan E Simmons; Kadir Erkmen; Keith D Paulsen; David W Roberts
Journal:  Neurosurgery       Date:  2014-03       Impact factor: 4.654

2.  Skull base meningiomas: neurological outcome after microsurgical resection.

Authors:  Judith Scheitzach; Karl-Michael Schebesch; Alexander Brawanski; Martin A Proescholdt
Journal:  J Neurooncol       Date:  2013-11-21       Impact factor: 4.130

3.  Two step approach for surgical removal of petroclival meningiomas with large supratentorial extension.

Authors:  Madjid Samii; Venelin Gerganov; Mario Giordano; Amir Samii
Journal:  Neurosurg Rev       Date:  2010-11-26       Impact factor: 3.042

4.  Quantitative and qualitative 5-aminolevulinic acid-induced protoporphyrin IX fluorescence in skull base meningiomas.

Authors:  Kimon Bekelis; Pablo A Valdés; Kadir Erkmen; Frederic Leblond; Anthony Kim; Brian C Wilson; Brent T Harris; Keith D Paulsen; David W Roberts
Journal:  Neurosurg Focus       Date:  2011-05       Impact factor: 4.047

5.  The role of Gamma Knife surgery in the treatment of skull base chordomas.

Authors:  Kasandra Dassoulas; David Schlesinger; Chun Po Yen; Jason Sheehan
Journal:  J Neurooncol       Date:  2009-03-11       Impact factor: 4.130

6.  Pterional approach versus unilateral frontal approach on tuberculum sellae meningioma: Single centre experiences.

Authors:  Muhammad Zafrullah Arifin; Ignatius Mardjono; Roland Sidabutar; Beny Atmadja Wirjomartani; Ahmad Faried
Journal:  Asian J Neurosurg       Date:  2012-01

7.  On a Rare Cutaneous Metastasis from a Sacrococcygeal Chordoma.

Authors:  Alessandro D'Amuri; Matteo Brunelli; Federica Floccari; Francesco De Caro; Giuliana Crisman; Francesca Sanguedolce; Marcello Filotico
Journal:  Case Rep Pathol       Date:  2017-03-19

8.  Frontolateral Approach Applied to Sellar Region Lesions: A Retrospective Study in 79 Patients.

Authors:  Hao-Cheng Liu; Zhen Wu; Liang Wang; Xin-Ru Xiao; Da Li; Wang Jia; Li-Wei Zhang; Jun-Ting Zhang
Journal:  Chin Med J (Engl)       Date:  2016-07-05       Impact factor: 2.628

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.